Quest Diagnostics announced a partnership with Helio Genomics that will make the HelioLiver blood‑based test for hepatocellular carcinoma (HCC) available to physicians and patients through Quest’s U.S. laboratory network beginning in April 2026.
HelioLiver uses a multi‑analyte approach that combines cell‑free DNA methylation patterns, serum protein biomarkers, and patient demographics, all analyzed by an AI algorithm. In the CLiMB clinical trial, the test demonstrated superior sensitivity to ultrasound for detecting small tumors in high‑risk patients, such as those with cirrhosis or hepatitis B. The test is offered as a laboratory‑developed test (LDT) and is already integrated into Quest’s existing phlebotomy and laboratory infrastructure.
The addition of HelioLiver fits neatly into Quest’s advanced diagnostics strategy, which focuses on high‑margin, high‑volume assays that can be scaled across its extensive network. By adding an early‑detection liver cancer test, Quest broadens its oncology screening portfolio and reinforces its position as a preferred laboratory partner for precision‑medicine diagnostics.
Helio Genomics, founded in 2016 and headquartered in Irvine, California, separated from its parent Laboratory for Advanced Medicine in 2024. The company has previously partnered with Fulgent Genetics to commercialize its early‑detection tests and has a portfolio that includes other liquid‑biopsy assays for different cancers.
While the financial terms of the agreement were not disclosed, the partnership is expected to generate additional revenue for Quest and expand its market reach into oncology screening, complementing its existing cardiometabolic, autoimmune, and brain‑health testing services. The move also aligns with Quest’s strategy of leveraging its national scale to deliver innovative diagnostics to a growing base of health‑system and consumer customers.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.